Metropolis Healthcare Limited — Investor Meet, 11-11-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Metropolis Healthcare reported Q2 FY26 Group revenue up 23% year-on-year, with organic revenue growing 12% and organic EBITDA margins expanding 60 bps to 26.8%. Management is focused on integrating recent acquisitions, enhancing efficiency, and driving organic growth. Plans include adding 300 collection centers in H2 and strengthening high-end specialized testing. Core Diagnostics integration is on track, aiming for double-digit margins by year-end. The company is exploring long-term diagnostic opportunities from GLP-1 therapies. Management expressed optimism about continued growth and market leadership, confident in achieving full-year guidance amidst stable competitive intensity.